Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| The other thing that the packaged products approach does is, it allows us to maximize the reach across our platform, which I believe in turn could yield better results for our clients |
| So I think that as we think about gross margin over time, due to the revenue outperformance we saw in Q3, we don't think we'll necessarily stay at this 93% level, but we feel pretty good about gross margins at 90% plus |
| So within our newsfeed, I think our newsfeed gets more and more relevant using machine learning, using AI, and that certainly has led to better program results for our clients, which is terrific |
| So doctors come in to write an insurance appeal letter or a service animal letter in our DocsGPT product, which as I mentioned in the prepared remarks, continues to grow nicely and organically |
| It's really good at helping you get the administrative work done to fight with the insurance companies or others more quickly |
| We also saw strong growth in newer brands |
| Yes, we're really pleased that we've grown the aperture |
| On that front, we're thrilled to announce that for the third year in a row, Doximity has been ranked the number 1 best-in-class telehealth video platform by health system CIOs and their staff, beating out Microsoft Teams, Zoom and many others |
| And that's something that we've been spending a lot of time on internally, and we're really excited about delivering that for our clients for next year |
| And I think it's great that we'll be able to continue to do that |
| Anna, you've talked in the prepared remarks and in the Q&A about a strong Q selling season, healthy revenue retention expectations for above market growth |
| And of course, that's great news for our clients, great news for the doctors, great news for the patients who need that medication |
| We're the best product in the market |
| So we're really excited about what we're doing here, and the strength we're seeing amongst these new modules |
| Our bottom line was also strong in Q3 with an adjusted EBITDA margin of 54% or $73 million, which was 18% above the high end of our guidance |
| I'm pleased to report that we delivered $135 million in revenue for the third quarter of our fiscal 2024, a 6% beat versus the high end of our guidance and 17% growth year-on-year |
| And if you're following along on the net revenue retention rates, the NRRs, you can see that we did increase slightly this last quarter on these, which I think is a strong sign that we're doing a great job of landing and expanding, especially the expanding, and we're just pleased that we have yet to, I think, really hit a glass ceiling inside any of these mega top 5, top 10 pharmaceutical companies or other large players |
| As I mentioned, new modules grew nicely, but we also saw really nice growth amongst some of our larger brands and a continued growth in that $10 million-plus cohort |
| We did see a record non-GAAP gross margin this last quarter at 93% |
| We have benefited from our increased focus on selling newer modules on a packaged basis as our customers continue to expand their reach across our entire platform |
| But we're really encouraged by the way they've ramped growing over 100% year-over-year and really the second year we're selling them |
| So we're really excited by the growth we saw amongst our newer modules |
| We also saw strength in our modules that often sit outside of traditional marketing budgets, such as Peer-to-Peer, Point-of-Care and Formulary |
| But what I will say is that we're really excited about the scale of buying we saw on our platform during the upfront season |
| We are encouraged by the levels of investment our customers are making in Doximity, and are excited by the opportunity to continue delivering innovative solutions, real-time insights and industry-leading ROI |
| Based on our upfront selling season, we are confident our pharma business can once again outpace the markets |
| So we're proud to have three $10 million new brands and our first-ever launch brand at $10 million |
| Third quarter revenue grew to $135.3 million, up 17% year-over-year and exceeding the high end of our guidance range |
| Motion today who are comfortable with these sorts of tools in the markets that they spend in and I think we'd see good ROI from our existing products |
| So we're really pleased with how we were able to end the year |
| Statement |
|---|
| That's due to macro uncertainty and continued, as I said, cyclical headwinds and end market budget growth |
| And the AI tool, as I mentioned in the prepared remarks, has been a real hit |
| I'll say the market growth rate that we're seeing is pretty in line with our expectations 90 days ago, as we're still in an uncertain macro, and we're still facing some cyclical headwinds in end market budget growth |
| There was a little bit less budget, I would say, to go around and that certainly affected us |
| I'd say the only criticism we've had on it so far is that they fear that we'll lock them out of it if they don't renew right away or don't spend more |
| Now that the company's a couple of quarters into say this lower market growth rate |
| And suffice it to say, the average doctor spends two hours doing administrative work for every one hour they spend seeing patients, which is an incredible problem in this country |
| Listen, like we said last quarter, like many other industries in this environment, we definitely saw some elongated sales cycles this past year |
| And that ended up slowing things down |
| Again, we're just being more caution longer, and this speaks to, I think, our change here in terms of just more conservatism in understanding that we are in a very uncertain market for a lot of reasons that our exogenous to us |
| So specifically, excluding the new products, would the sequential growth rate in 4Q '24 look more like 4Q '23, kind of down mid-single digits |
| What we're seeing from a step-down perspective is, in Q4, is the result of two factors |
| They're asking us how much it will cost just to get access to it, which is a good problem to have |
| But just any feel on that front would be good |
Please consider a small donation if you think this website provides you with relevant information